GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022

(Photo by Ben STANSALL / AFP) (Photo by BEN STANSALL/AFP via Getty Images)

AFP via Getty Images

Deal Overview

On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare. Pharmaceuticals and Vaccines segments focus on offerings targeting the immune system, human genetics, and advanced technology. The Consumer Healthcare business comprises major brands targeting oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements. Post separation, the stub unit will operate as a biopharma company concentrated on specialty medicines and vaccines, while the spin-off unit will focus on category-leading power brands.


GlaxoSmithKline Price Performance

Read more…